Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu, PR China; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, PR China.
School of Life Science and Engineering, Southwest University of Science and Technology, PR China.
Biomed Pharmacother. 2017 Aug;92:187-195. doi: 10.1016/j.biopha.2017.05.054. Epub 2017 May 22.
In the past 30 years, a variety of phage libraries have been extensively utilized to identify and develop tumor homing peptides (THPs). THPs specifically bind to tumor cells or elements of the tumor microenvironment while no or low affinity to normal cells. In this regard, the efficacy of therapeutic agents in cancer therapy can be enhanced by targeting strategies based on coupling with THPs that recognize receptors expressed by tumor cells or tumor vasculature. Especially, vascular-homing peptides, targeting tumor vasculature, have their receptors expressed on or around the blood vessel including pro-angiogenic factors, metalloproteinase, integrins, fibrin-fibronectin complexes, etc. This review briefly summarizes recent studies on identification and therapeutic applications of vascular-homing peptides targeting common angiogenic markers or with unknown vascular targets in some certain types of cancers. These newly discovered vascular-homing peptides are promising candidates which could provide novel strategies for cancer therapy.
在过去的 30 年中，已经广泛利用各种噬菌体文库来鉴定和开发肿瘤归巢肽（THP）。THP 特异性地与肿瘤细胞或肿瘤微环境的成分结合，而对正常细胞的亲和力低或无。在这方面，通过与识别肿瘤细胞或肿瘤血管表达的受体的 THP 偶联的靶向策略，可以增强治疗剂在癌症治疗中的疗效。特别是，靶向肿瘤血管的血管归巢肽，其受体表达在血管上或周围，包括促血管生成因子、金属蛋白酶、整合素、纤维蛋白-纤维连接蛋白复合物等。本文简要总结了最近关于鉴定和治疗应用的研究，这些研究涉及针对某些类型癌症中的常见血管生成标志物或具有未知血管靶点的血管归巢肽。这些新发现的血管归巢肽是很有前途的候选物，它们为癌症治疗提供了新的策略。
